MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

Samyang Corporation

Samyang Pharmaceuticals Business Unit, in collaboration with Samyang's pharmaceutical research center, is engaged in the development and marketing of novel drug delivery systems and medical devices.

The company in detail

Profile

Samyang Corporation is the parent company of Samyang Group. Samyang Corporation is engaged in pharmaceutical business through its Pharmaceuticals Business Unit. Samyang Corporation has established its unique position in the pharmaceutical industry as a company specialized in the drug delivery systems, developing advanced drug delivery systems and medical devices using in-depth experiences in polymer chemistry and collaborative relationships with companies in Korea and US.

During the time, Samyang Corporation Success has secured several kinds of platform technologies for DDS in oral, transdermal, parenteral delivery area.
In oral delivery area, Samyang Corporation has established its proprietary orally disintegrating tablet technology and colon-specific delivery technology which is applicable to various kinds of drugs in conventional manufacturing facility for oral formulation.

Samyang Corporation has also accumulated its know-how and proprietary technologies in transdermal delivery area as one of the best manufacturer for transdermal products in Korea.
Parenteral delivery area is based on the biocompatible polymer technology which is applied for the solubilization of insoluble drugs and sustained delivery of injectables.

Samyang has commercialized anti-inflammation transdermal patch (Diclofenac plaster), patches for smoking cessation (Nicotine patch), paclitaxel formulations and so on. Samyang Corporation owns KGMP-approved morden manufacturing plant for transdermals and medical devices and Samyang Genex (subsidiary company of Samyang) also owns oncology injectable manufacturing plant as well as oncology API manufacturing plant.

The combination of drug delivery technology and manufacturing expertise is the key strength of Samyang Corporation.

Partnering strategy/interests

The preferred partner for Samyang is a company who would like to license Samyang's products and technologies and develop further in its respective territories of interest. However, Samyang Corporation is open to any kinds of partnering strategy including co-development of specific products, contract manufacturing of transdermal products, and so on.

Out-licensing

Samyang is developing capsaicin patch for neuropathic pains such as post-herpetic neuralgia, diabetic neuropathy and so on. Capsaicin is delivered to the painful sites for three days with one plaster to specifically block the neuronal signal for pain. More
Samyang’s polymeric micelle formulation of Docetaxel is a lyophilized formulation which is soluble to water. Docetaxel-PM has the same pharmacological activity to original product, Taxotere of Sanofi-Aventis. More
Frosta technology is Samyang's patented technology for orally disintegrating tablet. It is applicable to conventional manufacturing facility with relatively simple manufacturing process for various kinds of drugs. More

Contact details

Mr. Hyungjin Jung
Senior Manager
Overseas Business Team

Contact directly

Head office

Samyang Corporation
263 Yeonji-dong
Chongno-Gu
Seoul
110-725
South Korea

Company figures

Formed: 1924
Annual Turnover: 1 Billion (2008)
Number of employees: 1200

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
The countdown has started...
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us